Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 3Various Advanced Cancer 2Stomach Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Microsatellite Unstable Colorectal Cancer 1Mesothelioma 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Glioma 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

Sunitinib 7Nivolumab 4pembrolizumab 3cabozantinib 2Ipilimumab 2Everolimus 2Axitinib 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1lenvatinib 1larotrectinib 1ipatasertib 1erdafitinib 1entrectinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1belzutifan 1avelumab 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Renal Cell × Nivolumab × Clear all
NCT02231749 2026-05-27

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Bristol-Myers Squibb

Phase 3 Completed
1,096 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04810078 2025-10-09

CheckMate-67T

Bristol-Myers Squibb

Phase 3 Active not recruiting
681 enrolled 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Bristol-Myers Squibb

Phase 3 Active not recruiting
701 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡